EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests

Noëlle Warmenhoven iD, Gemma Salvadó iD, Shorena Janelidze, Niklas Mattsson-Carlgren iD, Divya Bali, Anna Orduña Dolado iD, Hartmuth Kolb, Gallen Triana-Baltzer, Nicolas R Barthélemy, Suzanne E Schindler, Andrew J Aschenbrenner iD, Cyrus A Raji und 12 weitere

Brain · 03.02.2025 · 148 (2) · 416-431

DOI: 10.1093/brain/awae346 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Brain, online erschienen am 28.10.2024. Verfasst von Noëlle Warmenhoven und 23 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö 211 46, Sweden. Hauptthemen laut MEDLINE: tau Proteins, Alzheimer Disease. Die Arbeit wurde bisher 146-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Knight ADRC Developmental Projects, Alzheimer's Association, Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plasma phosphorylated-tau 217 (p-tau217) is currently the most promising biomarker for reliable detection of Alzheimer’s disease pathology. Various p-tau217 assays have been developed, but their relative performance is unclear. We compared key plasma p-tau217 tests using cross-sectional and longitudinal measures of amyloid-β (Aβ)-PET, tau-PET and cognition as outcomes and benchmarked them against CSF biomarker tests. Samples from 998 individuals [mean (range) age 68.5 (20.0–92.5) years, 53% female] from the Swedish BioFINDER-2 cohort, including both cognitively unimpaired and cognitively impaired individuals, were analysed. Plasma p-tau217 was measured with mass spectrometry assays [the ratio between phosphorylated and non-phosphorylated (%p-tau217WashU) and p-tau217WashU] and with immunoassays (p-tau217Lilly, p-tau217Janssen and p-tau217ALZpath). CSF biomarkers included p-tau217Lilly, the US Food and Drug Administration-approved p-tau181/Aβ42Elecsys, and p-tau181Elecsys. All plasma p-tau217 tests exhibited a high ability to detect abnormal Aβ-PET [area under the curve (AUC) range: 0.91–0.96] and tau-PET (AUC range: 0.94–0.97). Plasma %p-tau217WashU had the highest performance, with significantly higher AUCs than all the immunoassays (Pdiff < 0.007). For detecting Aβ-PET status, %p-tau217WashU had an accuracy of 0.93 (immunoassays: 0.83–0.88), sensitivity of 0.91 (immunoassays: 0.84–0.87) and a specificity of 0.94 (immunoassays: 0.85–0.89). Among immunoassays, p-tau217Lilly and plasma p-tau217ALZpath had higher AUCs than plasma p-tau217Janssen for Aβ-PET status (Pdiff < 0.006), and p-tau217Lilly outperformed plasma p-tau217ALZpath for tau-PET status (Pdiff = 0.025). Plasma %p-tau217WashU exhibited stronger associations with all PET load outcomes compared with immunoassays; baseline Aβ-PET load (R2: 0.72; immunoassays: 0.47–0.58; Pdiff < 0.001), baseline tau-PET load (R2: 0.51; immunoassays: 0.38–0.45; Pdiff < 0.001), longitudinal Aβ-PET load (R2: 0.53; immunoassays: 0.31–0.38; Pdiff < 0.001) and longitudinal tau-PET load (R2: 0.50; immunoassays: 0.35–0.43; Pdiff < 0.014). Among immunoassays, plasma p-tau217Lilly was more associated with Aβ-PET load than plasma p-tau217Janssen (Pdiff < 0.020) and with tau-PET load than both plasma p-tau217Janssen and plasma p-tau217ALZpath (all Pdiff < 0.010). Plasma %p-tau217 also correlated more strongly with baseline cognition (Mini-Mental State Examination) than all immunoassays (R2: %p-tau217WashU: 0.33; immunoassays: 0.27–0.30; Pdiff < 0.024). The main results were replicated in an external cohort from Washington University in St Louis (n = 219). Finally, p-tau217NULISA showed similar performance to other immunoassays in subsets of both cohorts. In summary, both mass spectrometry- and immunoassay-based p-tau217 tests generally perform well in identifying Aβ-PET, tau-PET and cognitive abnormalities, but %p-tau217WashU performed significantly better than all the examined immunoassays. Plasma %p-tau217 may be considered as a stand-alone confirmatory test for Alzheimer’s disease pathology, whereas some immunoassays might be better suited as triage tests where positive results are confirmed with a second test, which needs to be determined by future reviews incorporating results from multiple cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsAlzheimer DiseaseHumansFemaleAgedMaleBiomarkersMiddle AgedAged, 80 and overPhosphorylationCross-Sectional StudiesAdultAmyloid beta-PeptidesPositron-Emission TomographyYoung AdultLongitudinal StudiesSwedenCohort Studies

Stichwörter der Autor:innen

Alzheimer’s diseaseCSF biomarkersp-tau217plasma biomarkers

Substanzen

tau ProteinsBiomarkersAmyloid beta-PeptidesMAPT protein, human

Autor:innen und Institutionen

  • Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö 211 46, Sweden.
  • Department of Neurology, Skåne University Hospital, Lund University, Malmö 205 02, Sweden.
  • Wallenberg Center for Molecular Medicine, Lund University, Lund 223 62, Sweden.
  • Neuroscience Biomarkers, Johnson and Johnson Innovative Medicine, San Diego, CA 92123, USA.
  • The Tracy Family SILQ Center, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Department of Neurology, Washington University School of Medicine, St. Louis, MO 63108, USA.

ORCID-Profile: Noëlle Warmenhoven, Gemma Salvadó, Niklas Mattsson-Carlgren, Anna Orduña Dolado, Andrew J Aschenbrenner, John C Morris, Laura Ibanez, Carlos Cruchaga, Randall J Bateman, Henrik Zetterberg, Oskar Hansson

Förderung

  • Knight ADRC Developmental Projects
  • Alzheimer's Association
  • Department of Defense
  • Swedish Research Council
  • Alzheimerfonden
  • Alzheimer's Association Zenith Fellows Award
  • Rönström Family Foundation
  • Lund University

Zitieren

APA

Warmenhoven, N., Salvadó, G., Janelidze, S., Mattsson-Carlgren, N., Bali, D., Orduña Dolado, A., Kolb, H., Triana-Baltzer, G., Barthélemy, N. R., Schindler, S. E., Aschenbrenner, A. J., Raji, C. A., Benzinger, T. L. S., Morris, J. C., Ibanez, L., Timsina, J., Cruchaga, C., Bateman, R. J., Ashton, N., …, & Hansson, O. (2025). A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain, 148(2), 416-431. https://doi.org/10.1093/brain/awae346

Vancouver

Warmenhoven N, Salvadó G, Janelidze S, Mattsson-Carlgren N, Bali D, Orduña Dolado A, et al. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain. 2025;148(2):416-431. doi:10.1093/brain/awae346

BibTeX
@article{Warmenhoven2025,
  author = {Warmenhoven, Noëlle and Salvadó, Gemma and Janelidze, Shorena and Mattsson-Carlgren, Niklas and Bali, Divya and Orduña Dolado, Anna and Kolb, Hartmuth and Triana-Baltzer, Gallen and Barthélemy, Nicolas R and Schindler, Suzanne E and Aschenbrenner, Andrew J and Raji, Cyrus A and Benzinger, Tammie L S and Morris, John C and Ibanez, Laura and Timsina, Jigyasha and Cruchaga, Carlos and Bateman, Randall J and Ashton, Nicholas and Arslan, Burak and Zetterberg, Henrik and Blennow, Kaj and Pichet Binette, Alexa and Hansson, Oskar},
  title = {A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests},
  journal = {Brain},
  year = {2025},
  volume = {148},
  number = {2},
  pages = {416--431},
  doi = {10.1093/brain/awae346}
}
Kostenlos starten →